Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ViaCord® Collaborates with the Center for International Blood and Marrow Transplant Research®

Published: Wednesday, May 01, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
PerkinElmer’s family cord blood banking business and international research organization collaborates to analyze quality and outcomes of cord blood stem cell units.

ViaCord, PerkinElmer’s family cord blood and tissue preservation business, is collaborating with the Center for International Blood and Marrow Transplant Research (CIBMTR) to collect, maintain and publish research from ViaCord’s cord blood stem cell transplants. This collaboration will expand knowledge of cord blood-derived stem cell applications throughout the medical and research community. To date, CIBMTR’s large network of transplant centers has resulted in the development of a clinical database of more than 30,000 cord blood transplant recipients for clinical decision-making, use in studies, and other research purposes with the goal of making a profound impact on the survival of cord blood transplant patients around the world. CIBMTR will work directly with ViaCord to collect and analyze data to better understand the quality and any outcome metrics of ViaCord’s released cord blood stem cell units as well as how the units are being used.

“Collaborating with CIBMTR, which has established the industry standard for collecting data around hematopoietic cellular therapy and regenerative medicine, allows us to simultaneously gain insights into the effectiveness of the cord blood stem cell units we have released for use as well as outcomes from their clinical application,” said Morey Kraus, Chief Scientific Officer, ViaCord. “We are then able to incorporate data from our transplanted units into the larger database, which may be accessed for other CIBMTR studies by the medical and scientific community to further their research and understanding of cord blood stem cells.”

ViaCord is working with CIBMTR to collect and publish data as well as identify outcomes unique to related or autologous (stem cells from the same patient) transplants. The collaboration will also enable the analysis of umbilical cord units released for potential future use in autologous cell therapy and regenerative medicine clinical trials, including Cerebral Palsy, Type 1 Diabetes and others.

“The science of cord blood and cord tissue stem cells is growing at a rapid pace,” said J. Douglas Rizzo, M.D., M.S., Associate Scientific Director, CIBMTR. “We are excited to collaborate with ViaCord to provide data and analytic expertise that will assist the development of the field through research.”

ViaCord's family cord blood banking services currently offers expectant families the opportunity to preserve their baby's umbilical cord blood for potential medical use by the child or a related family member. Families are also preserving their baby’s umbilical cord tissue because research suggests that one day these special cells may have the potential to treat medical conditions that are untreatable today. ViaCord has preserved the umbilical cord blood of more than 300,000 newborns. Twenty years ago, cord blood stem cells were used to treat just one disease, Fanconi's anemia. Today, cord blood stem cells have been used in the treatment of nearly 80 diseases, including cancers, certain blood disorders and immunodeficiencies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PerkinElmer Sells NTD to Eurofins
PerkinElmer has announced that it sold its U. S. prenatal screening laboratory services business PerkinElmer Labs/NTD ("NTD") to Eurofins Scientific.
Tuesday, April 26, 2016
PerkinElmer Signals™ Perspectives Launches in Collaboration with Attivio
New data discovery solution leverages Attivio's platform to provide insight into complex scientific challenges.
Tuesday, February 02, 2016
PerkinElmer Collaborates with Waters on Chromatography Solutions
PerkinElmer, Inc. has announced a chromatography collaboration with Waters Corporation to deliver market leading software and premium instruments to PerkinElmer’s customers.
Wednesday, February 18, 2015
PerkinElmer, Sofie Biosciences Announce Benchtop PET Imaging Partnership
Preclinical PET imaging instruments in benchtop format help support high performance disease research, drug discovery and clinical translational applications.
Tuesday, June 10, 2014
Good Start Genetics, PerkinElmer Collaboration Expands Access to Genetic Carrier Screening Tests
Strategic agreement will broaden access to GoodStart Select™ tests to include obstetrics and gynecology and maternal fetal medicine physicians.
Monday, March 17, 2014
PerkinElmer Revenues Grow 4%
PerkinElmer, Inc. reported financial results for the fourth quarter ended December 29, 2013.
Monday, February 03, 2014
CAS and PerkinElmer Combine the Power of SciFinder and ChemBioDraw
New functionality will enable ChemBioDraw users to search in SciFinder, providing access to comprehensive content available in the CAS databases.
Tuesday, December 17, 2013
PerkinElmer Announces Strategic Alliance with Integromics
PerkinElmer becomes the sole worldwide distributor of Integromics’ software for the TIBCO Spotfire.
Tuesday, June 25, 2013
PerkinElmer to Host Revolutionaries for Global Health Summit
Company to assemble thought leaders to share pioneering personalized health research and innovations.
Wednesday, May 01, 2013
PerkinElmer and MGH Pathology Collaborate
Collaboration to develop a complete sequencing informatics system for cancer research.
Wednesday, September 12, 2012
PerkinElmer and TPM Biotech SDN. BHD. Partner to Validate Screening Application for Halal Food Products
Companies collaborate to explore potential applications of PerkinElmer’s Porcine Detection Kits and chromatography solutions for use in validating methods of testing food products for compliance with Halal certification regulations.
Tuesday, April 10, 2012
PerkinElmer Announces Collaboration with Rutgers University Cell and DNA Repository
Companies team up to enable large-scale sequencing studies through more efficient automation and improving next generation sequencing sample access.
Tuesday, February 21, 2012
PerkinElmer Announces Collaboration with Rutgers University Cell and DNA Repository
Rutgers University Cell and DNA Repository has adopted PerkinElmer’s technologies for automation of Next Generation Sequencing sample preparation.
Thursday, February 16, 2012
PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates
The company announced the launch of four new cellular assay kits to help identify and characterize possible drug candidates targeting epigenetic enzymes related to key disease states.
Tuesday, February 07, 2012
PerkinElmer to Acquire Caliper Life Sciences
PerkinElmer, Inc. announces that it has signed a definitive agreement to acquire Caliper Life Sciences, Inc. for a total net purchase price of approximately $600 million.
Wednesday, September 21, 2011
Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!